Trulieve Cannabis Corp.
TRLV
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $2.1B
$12.11
▲ +1.00%
P/E
-5.77
Mkt Cap
$2.1B
52-Wk Range
$4.62–$13.28
52-Week Range
$4.62 - $13.28
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 61.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-6.8% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying TRLV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 6, 2026
Reported EPS of -$2.11 vs $0.09 consensus (-2544.1% surprise). Revenue of $271.0M vs $268.5M expected (+0.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2544.1%
Revenue trend · last 2Q
—
-10%
Q1 26
Q2 26
$286.8M
$271.0M
Margins · last 2Q
Gross
59.9%
Operating
-136.8%
Profit
-149.8%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Jul 20, 2026
vs Industry
How TRLV stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.